Table 5.
Small molecules and drugs related to ferroptosis.
| Classification | Reagent | Signal target | Test cells | FDA Approved/Clinical Use | Reference |
|---|---|---|---|---|---|
| Ferroptosis inducer | Erastin and its analogs | System Xc-; VDAC2/3 | HT-1080 cell; A-673 cell; Calu-1 cell; BJeLR cell, etc. | No | (Yagoda et al., 2007; Dixon et al., 2012) |
| Sorafenib | System Xc- | HCC cell; HT-1080 cell; Calu-1 cell, etc. | Yes/Renal cell carcinoma and hepatocellular carcinoma treatment | (Louandre et al., 2013; Dixon et al., 2014; Louandre et al., 2015) | |
| Sulfasalazine(SAS) | System Xc-; GPX4 | Nb2-SFJCD1 cell; HT-1080 cell; BJeLR cell, etc. | Yes/Ulcerative colitis and rheumatoid arthritis treatment | (Gout et al., 2001; Sehm et al., 2016) | |
| Artemisinin and its derivatives | GSH depletion; Increased cellular iron | PDAC cell lines | Yes/Malaria treatment | (Eling et al., 2015) | |
| Buthionine sulfoximine (BSO) | GSH depletion | Pfa1 cell; BJeLR cell, etc. | No/Clinical trial for neuroblastoma treatment | (Harris et al., 2015; Yang et al., 2014) | |
| Cisplatin (CDDP) | GSH depletion | H1299 cell; A549 cell; HCT116 cell; MEFs, etc. | Yes/Treatment of various cancers | (Guo et al., 2018; Sato et al., 2018) | |
| (1S, 3R)-RSL3 | GPX4 | HT-1080 cell; Calu-1 cell; BJeLR cell, etc. | No | (Hangauer et al., 2017; Dixon et al., 2012) | |
| DPI7 | GPX4 | KBM7 cell | No | (Dixon et al., 2015; Yang et al., 2014) | |
| FIN56 | GPX4 and SQS | HT-1080 cell; BJeLR cell, etc. | No | (Shimada et al., 2016) | |
| FINO2 | Iron oxidation; Indirect inhibition of GPX4 | HT-1080 cell | No | (Gaschler et al., 2018) | |
| Statins | Block biosynthesis of CoQ10 | HCC4006 cell | Yes/Hypolipidemic | (Viswanathan et al., 2017) | |
| Lapatinib | Iron transport blocker | MDA MB 231 cell; SkBr3 cell | Yes/Breast cancer treatment | (Ma et al., 2017a) | |
| Siramesine | Increased cellular iron | MDA MB 231 cell; SkBr3cell | Yes | (Ma et al., 2017a) | |
| Ferroptosis inhibitor | Vitamin E | Antioxidants | Q7 cells | Yes/Prevent habitual abortion | (Hinman et al., 2018) |
| Baicalein | Activate Nrf2 pathway | PANC1 cell; BxPc3 cell | Yes | (Xie et al., 2016) | |
| Deferoxamine mesylate | Intracellular iron | BJeLR cell | Yes/Severe thalassemia treatment | (Yang and Stockwell, 2008) |